PMID- 19183164
OWN - NLM
STAT- MEDLINE
DCOM- 20090623
LR  - 20121115
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 64
IP  - 6
DP  - 2009 Jun
TI  - Randomized double-blind, placebo-controlled trial of sublingual immunotherapy 
      with a Pru p 3 quantified peach extract.
PG  - 876-83
LID - 10.1111/j.1398-9995.2008.01921.x [doi]
AB  - BACKGROUND: Peach allergy is highly prevalent in the Mediterranean area; it is 
      persistent and potentially severe, and therefore a prime target for 
      immunotherapy. We aimed to study the efficacy and safety of sublingual 
      immunotherapy (SLIT) with a peach extract quantified in mass units for Pru p 3, 
      the peach lipid transfer protein. METHODS: Randomized, double-blind, 
      placebo-controlled (DBPC) clinical trial. The main efficacy outcome was the 
      change in the response to a DBPC food challenge (DBPCFC) with peach. Secondary 
      efficacy outcomes were the changes in skin prick test (SPT), and in specific 
      immunoglobulin E (IgE) and IgG(4) to Pru p 3. Tolerance was assessed with a 
      careful recording of adverse events. RESULTS: After 6 months of SLIT, the active 
      group tolerated a significantly higher amount of peach (three- to ninefold), 
      presented a significant decrease (5.3 times) in SPT, and a significant increase 
      in IgE and IgG(4) to Pru p 3. No significant changes were observed within the 
      placebo group. Statistically significant inter-group differences were only 
      observed in the SPT and IgG(4) responses. No serious adverse events were 
      reported. Systemic reactions were mild, and observed with a similar frequency in 
      both groups. Local reactions were significantly more frequent in the active group 
      (three times) and 95% of them restricted to the oral cavity. CONCLUSION: In this 
      first exploratory clinical trial, SLIT for peach allergy seems to be a promising 
      therapeutic option that could modify the clinical reactivity of the patients to 
      peach intake and the underlying immunological response with a good tolerance.
FAU - Fernandez-Rivas, M
AU  - Fernandez-Rivas M
AD  - Unidad de Alergia, Fundacion Hospital Alcorcon, Alcorcon, Spain.
FAU - Garrido Fernandez, S
AU  - Garrido Fernandez S
FAU - Nadal, J A
AU  - Nadal JA
FAU - Diaz de Durana, M D Alonso
AU  - Diaz de Durana MD
FAU - Garcia, B E
AU  - Garcia BE
FAU - Gonzalez-Mancebo, E
AU  - Gonzalez-Mancebo E
FAU - Martin, S
AU  - Martin S
FAU - Barber, D
AU  - Barber D
FAU - Rico, P
AU  - Rico P
FAU - Tabar, A I
AU  - Tabar AI
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090121
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
RN  - 0 (Antigens, Plant)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Plant Proteins)
RN  - 0 (Pru p 3 allergen)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Administration, Sublingual
MH  - Adult
MH  - Allergens/*administration & dosage/immunology
MH  - Antigens, Plant
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Double-Blind Method
MH  - Female
MH  - Food Hypersensitivity/*therapy
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Plant Proteins
MH  - Prunus/*immunology
MH  - Skin Tests
EDAT- 2009/02/03 09:00
MHDA- 2009/06/24 09:00
CRDT- 2009/02/03 09:00
PHST- 2009/02/03 09:00 [entrez]
PHST- 2009/02/03 09:00 [pubmed]
PHST- 2009/06/24 09:00 [medline]
AID - ALL1921 [pii]
AID - 10.1111/j.1398-9995.2008.01921.x [doi]
PST - ppublish
SO  - Allergy. 2009 Jun;64(6):876-83. doi: 10.1111/j.1398-9995.2008.01921.x. Epub 2009 
      Jan 21.